


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated:

Sept 1, 2004

By:



Jane K. Babin

Reg. No. 47,224

PAUL, HASTINGS, JANOFSKY & WALKER LLP

P.O. Box 919092

San Diego, CA 92191-9092

Phone: (858) 720-2500

Fax: (858) 720-2555



Patent
39038.00002.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Sylvain, Chemtob et al.

Serial No.: 10/678,413

Filed: October 02, 2003

For: **G PROTEIN-COUPLED RECEPTOR
AGONISTS OR ANTAGONISTS**

)
) **Group Art Unit: 1614**

)
) **Examiner: To be assigned**

)
) **Customer No.: 36183**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicant's duty under 37 CFR § 1.56, the following information is brought to the attention of the Examiner.

CERTIFICATE OF MAILING
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Date of Delivery

September 2, 2004

Timothy Lasher
Name of Person Delivering Paper

Timothy Lasher
Signature of Person Delivering Paper

REFERENCES



The references are listed on the attached Form PTO/SB/08a and copies are enclosed for the convenience of the Examiner.



Copies of the references listed on the attached Form PTO/SB/08a have already been submitted in corresponding Patent Application No. _____ and therefore, copies of the same are not enclosed.



Pursuant to the Patent Office waiver of 37 C.F.R. 1.98(a)(2)(i) (<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm>), copies of U.S. Patents and U.S. Patent application publications are not enclosed herewith.

The items identified in this Information Disclosure Statement may or may not be “material” pursuant to 37 CFR § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

DISCLOSURE

☒ The attached IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c)

☐ The attached Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under § 1.113 or a Notice of Allowance under § 1.311. In the event that this IDS is not received before a Final Action under § 1.113 or a Notice of Allowance under § 1.311, the Applicant respectfully requests the filing of these papers to be considered a petition requesting consideration of this IDS pursuant to 37 CFR § 1.97(d).

☐ The attached Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(d) and 1.98. This IDS is being filed after receipt of a final action but before receipt of a Notice of Allowance Under § 1.311.

Statement Under 37 C.F.R. 1.97(e)(1) and 1.97(e)(2)

☐ I certify that pursuant to 37 CFR 1.97(e)(1), each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

☐ I certify that pursuant to 37 CFR 1.97(e)(2), no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the best of my knowledge, no item of information contained in this Information Disclosure Statement was known to any individual more than three months prior to the filing of this Information Disclosure Statement.

PAYMENT METHOD

☐ Enclosed is a check to cover the fee pursuant to 37 CFR § 1.17(p).


☒ The Examiner is hereby authorized to charge any fee due with this filing to our Deposit Account No. **50-2613**.

☐ The Examiner is hereby authorized to charge any additional fee(s) required by this paper to our Deposit Account No. **50-2613**.


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER

Dated: September 1, 2004

By: 
Jane K. Babin
Reg. No. 47,224

P.O. Box 919092
San Diego, California 92191-9092
Telephone: (858) 720-2500
Facsimile: (858) 720-2555



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/678,413	
			Filing Date	October 02, 2003	
			First Named Inventor	Sylvain, Chemtob et al.	
			Group Art Unit	1614	
			Examiner Name	To be assigned	
Sheet	1	of	5	Attorney Docket Number	39038.00002.CIP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AA		WO 97/12624		Defeo-Jones et al.	04-10-1997		
	AB		WO 96/19233		Demopulos et al.	06-27-1996		
	AC		WO 96/06856		Webber, Robert	03-07-1996		
	AD		WO 95/29193		Kawakami, Yutaka et al	11-02-1995		
	AE		WO 95/11987		Scott, Randy et al.	05-04-1995		
	AF		WO 94/020127 A1		Grey, Howard M. et al.	09-15-1994		
	AG		WO 99/55849		Honeyman, Margo et al.	11-04-1999		
	AH		WO 98/26070		Cherk, Tam	06-18-1998		
	AI		WO 97/34621		Grey, Howard et al.	09-25-1997		
	AJ		WO 97/18236		Miller, Jonathon et al.	05-22-1997		
	AK		EP 0045665		Szelke, Michael et al.	09-04-1985		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AL	ABRAN, DANIEL et al. "Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs" The American Physiological Society, 1997, Pages R995 - R1001.	

Examiner Signature	SAN/97452.1	Date Considered	
-----------------------	-------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/678,413
		Filing Date	October 02, 2003
		First Named Inventor	Sylvain, Chemtob et al.
		Group Art Unit	1614
		Examiner Name	To be assigned
Sheet	2	of	5
		Attorney Docket Number	39038.00002.CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	ALMQUIST, RONALD G. et al. "Synthesis and Biological Activity of a Ketomethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme" J. Med. Chem. 1980, 23, 1392-1398.	
	AN	BALDWIN, JOYCE M. et al. "An Alpha-carbon Template for the Transmembrane Helices in the Rhodopsin Family of G-protein-coupled Receptors" J. Mol. Biol. (1997) 272, 144-164.	
	AO	BASTIEN, LISON et al. "Cloning, Functional Expression, and Characterization of the Human Prostaglandin E2 Receptor EP2 Subtype" The Journal of Biological Chemistry, Vol. 269, No. 16, pp. 11873-11877, 1994.	
	AP	BHATTACHARYA, MOUSUMI et al. "Developmental Changes in Prostaglandin E2 Receptor Subtypes in Porcine Ductus Arteriosus, Possible Contribution in Altered Responsiveness to Prostaglandin E2" Circulation, October 19, 1999; 100: 1751-1756.	
	AQ	BREYER, MATTHEW D. et al. "Differential localization of prostaglandin E receptor subtypes in human kidney" Rapid Communication, F912 - F918.	
	AR	BREYER, MATTHEW D. et al. "Regulation of renal function by prostaglandin E receptors" Kidney International, Vol. 54, Suppl. 67, (1998) S88-S94.	
	AS	CRANKSHAW, D.J. et al. "Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contractility of the human lower uterine segment in vitro" Can. J. Physiol. Pharmacol. Vol. 72, 1994, 870-874.	
	AT	CRANKSHAW, D.J. et al. "Effects of Prostanoids on the Rat's Myometrium In Vitro during Pregnancy" Biology of Reproduction 46, 392-400 (1992).	
	AU	FRIEDLANDER, GERARD et al. "PGE2 Binding Sites and PG-Stimulated Cyclic AMP Accumulation in Rat Isolated Glomeruli and Glomerular Cultured Cells" Molecular and Cellular Endocrinology, 30 (1983) 201-214.	
	AV	GOODMAN, MURRAY et al. "The Synthesis and Conformational Analysis of Retro-Inverso Analogues of Biologically Active Molecules" Perspectives in Peptide Chemistry, 1981, pp. 283-294.	
	AW	GYETVAI, KRISTEN et al. "Tocolytics for Preterm Labor: A Systematic Review" The American College of Obstetricians and Gynecologists, Vol. 94, No. 5, Part 2, November 1999, pp.869-877.	
	AX	HANN, MICHAEL M. et al "On the Double Bond Isostere of the Peptide Bond: Preparation of an Enkephalin Analogue" J.C.S. Perkin, 1982, pp. 307-314.	
Examiner Signature	SAN/97452.1		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/678,413
				Filing Date	October 02, 2003
				First Named Inventor	Sylvain, Chemtob et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	3	of	5	Attorney Docket Number	39038.00002.CIP

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	AY	HAY, DOUGLAS W. P. et al. "Human urotensin-II is a potent spasmogen of primate airway smooth muscle" British Journal of Pharmacology (2000), 131, pp. 10-12.			
	AZ	"HEBERT, TERENCE E. et al. "A Peptide Derived from a B2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation" The Journal of Biological Chemistry, Vol. 271, No. 27, pp. 16384-16392, 1996.			
	BA	HOLLADAY, MARK W. et al. "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres" Tetrahedron Letters, Vol. 24, No. 41, pp. 4401-4404, 1983.			
	BB	HRUBY, VICTOR J. "Conformational Restrictions of Biologically Active Peptides via Amino Acid Side Chain Groups" Life Sciences, Vol. 31, pp. 189-199 (1982).			
	BC	HUDSON, DEREK et al. "Methionine Enkephalin and Isosteric Analogues" Int. j. Peptide Protein Res. 14, 1979, pp. 177-185.			
	BD	ICHIKAWA, A. et al. "Molecular aspects of the structures and functions of the prostaglandin E receptors" J. Lipid Mediators Cell Signalling 14(1996) pp. 83-87.			
	BE	JAMES, GUY L. et al. "Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells" Science, Vol. 260, 25 June 1993, pp. 1937-1942.			
	BF	JENNINGS-WHITE, CLIVE et al. "Synthesis of Ketomethylene Analogs of Dipeptides" Tetrahedron Letters, Vol. 23, No. 25, pp. 2533-2534, 1982.			
	BG	LAKE, S. et al. "Cloning of the rat and human prostaglandin F2a receptors and the expression of the rat prostaglandin F2a receptor" Federation of European Biochemical Societies, 355, (1994) 317-325.			
	BH	LEE, PIL RYANG et al. "Therapeutic effect of cyclo-oxygenase inhibitors with different isofarm selectivity in lipopolysaccharide-induced preterm birth in mice" Am J Obstet General, Volume 189, No. 1 (2003), pp. 262-266.			
	BI	LOFTS, F.J. et al. "Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor <i>in vitro</i> and <i>in vivo</i> " Oncogene (1993) 8, 2813-2820.			
	BJ	LUMSDEN, M.A. et al. "Is Prostaglandin F2 Involved in the Increased Myometrial Contractility of Primary Dysmenorrhoea?" Prostaglandins, May 1983 Vol. 25 No. 5, pp. 683-692.			
Examiner Signature	SAN/97452.1		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/678,413
		Filing Date	October 02, 2003
		First Named Inventor	Sylvain, Chemtob et al.
		Group Art Unit	1614
		Examiner Name	To be assigned
		Attorney Docket Number	39038.00002.CIP
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BK	MORALES, WALTER J. et al. "Efficacy and Safety of Indomethacin Versus Ritodrine in the Management of Preterm Labor: A Randomized Study" Obstetrics & Gynecology, Vol. 74, No. 4, October 1989, pp. 567-572.	
	BL	MORATH, RUTA et al. "Immunolocalization of the Four Prostaglandin E2 Receptor Proteins EP1, EP2, EP3, and EP4 in Human Kidney" J. Am Soc Nephrol 10: 1851-1860, 1999.	
	BM	MORLEY, J.S. "Modulation of the action of regulatory peptides by structural modification" TIPS, December 1980, pp. 463-468.	
	BN	NARUMIYA, SHUH et al. "Prostanoid Receptors: Structures, Properties, and Functions" Physiological Reviews, Vol. 79, No. 4, October 1999, pp. 1193-1226.	
	BO	NGUYEN, MYTRANG et al. "The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth" Letters to Nature, Vol. 390, November 6, 1997, pp.78-81.	
	BP	NOVY, MILES J. et al. "Role of Prostaglandins, Prostacyclin and Thromboxanes in the Physiologic Control of the Uterus and in Parturition" Seminars in Perinatology, Vol. 4, No. 1 (January), 1980, pp. 45-66	
	BQ	PERI, KRISHNA G. et al. "THG113: A Novel Selective FP Antagonist that Delays Preterm Labor" Seminars in Perinatology, Vol. 26, No. 6 (December), 2002, pp. 389-397.	
	BR	POWELL, ANDREA M. et al. "Menstrual-PGF2a, PGE2, and TXA2 in Normal and Dysmenorrheic Women and Their Temporal Relationship to Dysmenorrhea" Prostaglandins, February 1985, Vol. 29, No. 2, pp. 273-293	
	BS	PULKINEN, M. O. "Alterations in Intrauterine Pressure, Menstrual Fluid Prostaglandin F Levels, and Pain in Dysmenorrheic Women Treated with Nimesulide" J. Clin. Pharmacol 1987; 27: pp. 65-69.	
	BT	REHWALD, MATTHIAS et al. "Possible role for Ligand binding of histidine 81 in the second transmembrane domain of the rat prostaglandin F2a receptor" FEBS Letters 443, (1999), pp. 357-362.	
	BU	RUDINGER, J. "Characteristics of the amino acids as components of peptide hormone sequence" pp. 1-7.	
	BV	SCHLONDORFF, DETLEF et al. "Prostaglandins and other arachidonic acid metabolites in the kidney" Kidney International, Vol. 29 (1986), pp. 108-119.	
Examiner Signature	SAN/97452.1		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/678,413
		Filing Date	October 02, 2003
		First Named Inventor	Sylvain, Chemtob et al.
		Group Art Unit	1614
		Examiner Name	To be assigned
		Attorney Docket Number	39038.00002.CIP
Sheet	5 of 5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BW	SCHRAMM, HANS J. et al. "The inhibition of human immunodeficiency virus proteases by interface peptides" Antiviral Research 30 (1996), pp. 155-170.	
	BX	SEGI, ERI et al. "Patent Ductus Arteriosus and Neonatal Death in Prostaglandin Receptor EP4-Deficient Mice" Biochemical and Biophysical Research Communications 246, 7-12 (1998) pp. 7-12.	
	BY	SENIOR, J. et al. "In Vitro characterization of prostanoid FP-, DP-, IP- and TP-Receptors on the non-pregnant human myometrium" J. Pharmacol (1992), 107, pp. 215-221.	
	BZ	SENIOR, J. et al. "In vitro characterization of prostanoid receptors on human myometrium at term of pregnancy" J. Pharmacol (1993) 108, pp. 501-506.	
	CA	SPATOLA, ARNO F. et al. "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates" Life Sciences, Vol. 38, pp. 1243-1249.	
	CB	SPATOLA, ARNO F. "Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates. Conformational Constraints, and Relations" Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins Vol. 7 pp. 267-356.	
	CC	SUGIMOTO, YUKIHIKO et al. "Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor kidney" Rapid Communication (1994) F823-F828.	
	CD	TAI, HITOSHI et al. "Transcriptional Induction of Cyclooxygenase-2 in Osteoblasts is Involved in Interleukin-6-Induced Osteoclast Formation" Endocrinology, Vol. 138, No. 6, pp. 2372-2379.	
	CE	"TAYLOR, JOAN M. et al. "Peptides as Probes for G Protein Signal Transduction" Cellular Signalling, Vol. 6, No. 8, pp. 841-849 (1994).	
	CF	UNGER, VINZENZ M. et al. "Arrangement of rhodopsin transmembrane α -helices" Letters to Nature, Vol. 389, 11 September 1997, pp. 203-206.	
	CG	WISE, H. "Activation of the Prostaglandin EP4- receptor subtype is highly coupled to inhibition of N-formyl-methionyl-leucyl-phenylalanine-stimulated rat neutrophil aggregation"	
	CH	YOUSIF, MARIAM H. et al. "Tocolytic Effect of the Cyclooxygenase-2-Inhibitor, Meloxicam: Studies on Uterine Contractions in the Rat" J. Pharm. Pharmacol, 1998, pp. 681-685.	
Examiner Signature	SAN/97452.1		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.